Related stories
OSE Immunotherapeutics Says Tedopi Combinations Meet Phase 2 Trial Primary Endpoint
OSE Immunotherapeutics said Tedopi combinations met the primary endpoint in a Phase 2 lung cancer trial.
M impact | EQUITY | Oct 29, 2026, 05:30 PM UTC
Glaukos shares soar 31% amid heavy trading
Glaukos shares rose 31% amid heavy trading.
M impact | EQUITY | Oct 29, 2026, 05:30 PM UTC
US session market picture: S&P 500 -0.51%, Nasdaq 100 -1.5%; EUR/USD +0.14%, WTI -1.15%, WBD leads volume
US session market picture. US index futures: S and P futures is down 0.51 percent, Nasdaq futures is down 1.5 percent, Dow futures is down 0.53 percent and Russell futures is up 1
M impact | EQUITY | Oct 29, 2026, 05:30 PM UTC
Toyota, Honda and Nissan Cut China Output on Weak Gas-Vehicle Demand
Nikkei Asia reports the automakers are cutting output in China amid low demand for gasoline vehicles.
M impact | EQUITY | Oct 29, 2026, 05:29 PM UTC
Restaurant Brands International Reports Quarterly Results
Restaurant Brands International reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 05:29 PM UTC
Tenet Healthcare Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 05:27 PM UTC